{"i": ["aminoglycoside antibiotics", "normal saline", "macrolides", "Dual release ciprofloxacin for inhalation ( DRCFI ) contains liposomal ciprofloxacin", "gentamicin", "oral antipseudomonal therapy", "liposomal ciprofloxacin", "DRCFI or matching placebo", "nebulised antibiotics", "control liposomes", "DRCFI or placebo", "free ciprofloxacin", "Inhaled SABA", "SA anticholinergic", "mannitol", "fluoroquinolone", "antibiotics", "non - fluoroquinolone ) antibiotics", "DRCFI", "recombinant human DNase I nor tobramycin solution for inhalation ( TSI / TOBI )", "aminoglycosides", "Intravenous antibiotics", "DRCFI )", "placebo", "ciprofloxacin .", "liposomal ciprofloxacin .", "Prednisone", "gentamicin10", "Matched placebo", "Inhaled LABA", "tobramycin", "TOBI", "Placebo", "Dual release ciprofloxacin", "placebo - controlled", "ciprofloxacin", "Inhaled LA anticholinergic", "Combination inhalers ( ICS / LABA )", "inhaled antibiotics", "Inhaled corticosteroids"], "o": ["AEs", "sputum production ( volume , colour , consistency or haemoptysis ), dyspnoea , cough , fever , wheezing , exercise tolerance ( or fatigue / lethargy / malaise ), FEV1 or FVC fall", "SGRQ scores", "pulmonary exacerbation outcomes", "tolerability", "antimicrobial efficacy", "exacerbations", "Failure to culture P aeruginosa", "time to first pulmonary exacerbation", "overall proportion of subjects requiring antibiotics for pulmonary exacerbation", "time to exacerbation", "product taste abnormal", "annual pulmonary exacerbations", "Respiratory - related AEs", "pulmonary exacerbation rates", "P aeruginosa bacterial load", "quality of life", "non - respiratory AEs", "headache", "exacerbation data and respiratory AEs", "duration of drug exposure", "safety and time to first pulmonary exacerbation", "time to first pulmonary exacerbation , forced expiratory volume in 1 s ( FEV1 ), 6MWT , SGRQ , safety and tolerability .", "bacterial density", "Pulmonary exacerbations", "6MWT distance", "nausea", "lung clearance half life", "respiratory AEs", "changes on chest radiograph and changes in chest sounds on auscultation .", "safety , tolerability", "first pulmonary exacerbation", "Time to pulmonary exacerbation", "SGRQ total score", "P aeruginosa ciprofloxacin minimal inhibitory concentrations", "sputum P aeruginosa bacterial counts", "sinusitis", "Sputum", "colony forming unit ( CFU ) count", "sputum P aeruginosa bacterial density", "spirometry , sputum collection , 6 min walk test ( 6MWT ) and St George ' s Respiratory Questionnaire ( SGRQ ).", "microbiological efficacy", "FEV1", "categorical susceptibility", "lung disorder", "tolerated", "respiratory - related AEs", "P aeruginosa bacterial density", "systemic adverse events", "New sputum pathogens", "change in sputum P aeruginosa bacterial density", "pulmonary adverse events .", "antipseudomonal microbiological efficacy", "bacterial counts", "median time to pulmonary exacerbation"]}